Silexion Therapeutics Corp. has completed its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. SIL-204 is a next-generation siRNA candidate designed to target a broad range of ...
Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This ...
Jushi Holdings Inc. ("Jushi” or the "Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis ...
Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
As of 9:35:22 AM EST. Market Open. Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results ...
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Thursday. The Dow traded up 0.26% to 44,829.59 while the NASDAQ gained 0.75% to 19,779.27. The S&P 500 ...
In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with a price target of $9.00. The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results